Clinical

Dataset Information

0

TheraSphere for the Treatment of Liver Metastases


ABSTRACT: This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies.

DISEASE(S): Neoplasm Metastasis,Carcinoma, Neuroendocrine,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2042885 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2093200 | ecrin-mdr-crc
2018-07-20 | GSE117400 | GEO
2012-05-31 | E-GEOD-33172 | biostudies-arrayexpress
| 2101871 | ecrin-mdr-crc
| PRJNA858191 | ENA
2019-12-01 | GSE117356 | GEO
2023-05-10 | PXD038776 | Pride
2016-07-07 | E-GEOD-84108 | biostudies-arrayexpress
2022-05-07 | GSE202120 | GEO
2022-03-18 | PXD025343 | Pride